Back

CYP2C19 and effect of clopidogrel for secondary prevention of major ischemic events: systematic review and meta-analysis

2023-08-20 cardiovascular medicine Title + abstract only
View on medRxiv
Show abstract

BackgroundCarriers of the CYP2C19 Loss of Function (LoF) allele may experience decreased efficacy of clopidogrel in secondary prevention after cardiovascular events. Randomized clinical trials of clopidogrel in patients with known CYP2C19 carrier status provided inconsistent results. Our aim was to pool the evidence on the effect of clopidogrel on outcome, according to CYP2C19 LoF status, in a meta-analysis. MethodsA systematic review and meta-analysis of randomized controlled trials (RCTs) on ...

Predicted journal destinations